Biogen Sued by Neuroscience Company Sage After Buyout Offer (1)

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the smaller neuroscience company for about $469 million.

The lawsuit remains under seal with Delaware’s Chancery Court, the leading US forum for merger fights and corporate cases. But a related public filing indicates Sage is seeking an injunction to enforce a standstill agreement against Biogen, its largest shareholder and partner on the postpartum depression drug Zurzuvae. Biogen currently holds a roughly 10% stake in Sage.

The court complaint followed a Jan. 10 public letter from Biogen CEO Chris Viehbacher—disclosing ...